Product Pipeline

Early Detection: Catching Cancer Sooner

One of the most promising uses of liquid biopsy is early cancer detection. Blood-based tests offer a crucial window of opportunity for timely intervention by identifying cancer biomarkers early, sometimes even before symptoms appear. In cancer, early warnings can significantly improve treatment outcomes and survival rates. In validation studies, Caris Assure detected malignancies at their earliest stages across various solid tumor types with 99.5% positive predictive value (PPV).

Tracking MRD for Better Outcomes

Liquid biopsies can be used to monitor disease progression and detect minimal residual disease (MRD) and recurrence. MRD detection involves identifying trace amounts of circulating tumor nucleic acids in the blood, which can remain after curative-intent treatments. Even small amounts of residual disease can indicate a risk of recurrence.

MRD detection enables clinicians to adjust treatment plans proactively, improving patient outcomes by facilitating early intervention and personalized treatment strategies. Data presented at AACR 2024 showed that Caris Assure effectively detects MRD in blood plasma.

Real-Time Insights into Therapeutic Response and Disease Progression

Blood-based assays that leverage comprehensive molecular profiling, such as Caris Assure, can detect early signs of treatment resistance or disease recurrence, enabling timely interventions tailored to the patient’s specific cancer profile. This ongoing treatment monitoring ultimately aims to improve patient outcomes and survival rates. In internal validation studies, Caris Assure functioned effectively as a monitoring tool.